{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:25:10Z","timestamp":1791321910909,"version":"4.3.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T00:00:00Z","timestamp":1519776000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s11095-018-2368-7","type":"journal-article","created":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T10:54:19Z","timestamp":1519815259000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Formulation Stabilization and Disaggregation of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions"],"prefix":"10.1007","volume":"35","author":[{"given":"Steven A.","family":"Giannos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward R.","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin H.","family":"Merkley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,28]]},"reference":[{"issue":"1","key":"2368_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4161\/19420862.2015.989042","volume":"7","author":"DM Ecker","year":"2015","unstructured":"Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. Mabs-Austin. 2015;7(1):9\u201314.","journal-title":"Mabs-Austin"},{"issue":"1","key":"2368_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4161\/19420862.2015.988944","volume":"7","author":"JM Reichert","year":"2015","unstructured":"Reichert JM. Antibodies to watch in 2015. Mabs-Austin. 2015;7(1):1\u20138.","journal-title":"Mabs-Austin."},{"issue":"7","key":"2368_CR3","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.jfo.2014.06.001","volume":"37","author":"M Weber","year":"2014","unstructured":"Weber M, Sennlaub F, Souied E, Cohen SY, Behar-Cohen F, Milano G, et al. Review and expert opinion in age related macular degeneration. Focus on the pathophysiology, angiogenesis and pharmacological and clinical data. Journal Francais D Ophtalmologie. 2014;37(7):566\u201379.","journal-title":"Journal Francais D Ophtalmologie"},{"issue":"7","key":"2368_CR4","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1002\/bit.23155","volume":"108","author":"M Vazquez-Rey","year":"2011","unstructured":"Vazquez-Rey M, Lang DA. Aggregates in monoclonal antibody manufacturing processes. Biotechnol Bioeng. 2011;108(7):1494\u2013508.","journal-title":"Biotechnol Bioeng"},{"issue":"5\u20136","key":"2368_CR5","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.addr.2006.03.011","volume":"58","author":"AL Daugherty","year":"2006","unstructured":"Daugherty AL, Mrsny RJ. Formulation and delivery issues for monoclonal antibody therapeutics. Adv Drug Deliv Rev. 2006;58(5\u20136):686\u2013706.","journal-title":"Adv Drug Deliv Rev"},{"key":"2368_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/B978-0-12-386483-3.00004-5","volume":"84","author":"D Lowe","year":"2011","unstructured":"Lowe D, Dudgeon K, Rouet R, Schofield P, Jermutus L, Christ D. Aggregation, stability, and formulation of human antibody therapeutics. Adv Protein Chem Struct Biol. 2011;84:41\u201361.","journal-title":"Adv Protein Chem Struct Biol"},{"issue":"2","key":"2368_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ijpharm.2010.02.025","volume":"390","author":"W Wang","year":"2010","unstructured":"Wang W, Nema S, Teagarden D. Protein aggregation--pathways and influencing factors. Int J Pharm. 2010;390(2):89\u201399.","journal-title":"Int J Pharm"},{"issue":"11","key":"2368_CR8","first-page":"44","volume":"21","author":"RV Cordoba-Rodriguez","year":"2008","unstructured":"Cordoba-Rodriguez RV. Aggregates in MAbs and Recombinant Therapeutic Proteins: A Regulatory Perspective. Biopharm Int. 2008;21(11):44\u201353.","journal-title":"Biopharm Int"},{"issue":"6","key":"2368_CR9","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1023\/B:PHAM.0000029275.41323.a6","volume":"21","author":"S Hermeling","year":"2004","unstructured":"Hermeling S, Crommelin DJA, Schellekens H, Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res. 2004;21(6):897\u2013903.","journal-title":"Pharm Res"},{"issue":"9","key":"2368_CR10","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1023\/A:1025771421906","volume":"20","author":"EY Chi","year":"2003","unstructured":"Chi EY, Krishnan S, Randolph TW, Physical CJF. Stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res. 2003;20(9):1325\u201336.","journal-title":"Pharm Res"},{"issue":"3","key":"2368_CR11","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3390\/antib2030452","volume":"2","author":"S Goswami","year":"2013","unstructured":"Goswami S, Wang W, Arakawa T, Ohtake S. Developments and challenges for mAb-based therapeutics. Antibodies. 2013;2(3):452\u2013500.","journal-title":"Antibodies"},{"issue":"1","key":"2368_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1208\/s12248-013-9539-6","volume":"16","author":"R Chaudhuri","year":"2014","unstructured":"Chaudhuri R, Cheng Y, Middaugh CR, Volkin DB. High-throughput biophysical analysis of protein therapeutics to examine interrelationships between aggregate formation and conformational stability. AAPS J. 2014;16(1):48\u201364.","journal-title":"AAPS J"},{"issue":"13","key":"2368_CR13","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.addr.2011.07.006","volume":"63","author":"TJ Kamerzell","year":"2011","unstructured":"Kamerzell TJ, Esfandiary R, Joshi SB, Middaugh CR, Volkin DB. Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development. Adv Drug Deliv Rev. 2011;63(13):1118\u201359.","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"2368_CR14","doi-asserted-by":"publisher","first-page":"613","DOI":"10.2174\/0929866054696109","volume":"12","author":"K Tsumoto","year":"2005","unstructured":"Tsumoto K, Ejima D, Kita Y, Arakawa T. Review: why is arginine effective in suppressing aggregation? Protein Pept Lett. 2005;12(7):613\u20139.","journal-title":"Protein Pept Lett"},{"key":"2368_CR15","doi-asserted-by":"crossref","unstructured":"Ndoja S, Lima H. 4 -Monoclonal Antibodies. In Current Developments in Biotechnology and Bioengineering: Elsevier; 2017. p. 71\u201395.","DOI":"10.1016\/B978-0-444-63660-7.00004-8"},{"issue":"11","key":"2368_CR16","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1016\/j.xphs.2017.06.017","volume":"106","author":"N Whitaker","year":"2017","unstructured":"Whitaker N, Xiong J, Pace SE, Kumar V, Middaugh CR, Joshi SB, et al. A formulation development approach to identify and select stable ultra-high-concentration monoclonal antibody formulations with reduced viscosities. J Pharm Sci. 2017;106(11):3230\u201341.","journal-title":"J Pharm Sci"},{"issue":"4","key":"2368_CR17","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1080\/19420862.2015.1046664","volume":"7","author":"S Morar-Mitrica","year":"2015","unstructured":"Morar-Mitrica S, Puri M, Beumer Sassi A, Fuller J, Hu P, Crotts G, et al. Development of a stable low-dose aglycosylated antibody formulation to minimize protein loss during intravenous administration. Mabs-Austin. 2015;7(4):792\u2013803.","journal-title":"Mabs-Austin."},{"issue":"10","key":"2368_CR18","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1002\/jps.23224","volume":"101","author":"OS Kumru","year":"2012","unstructured":"Kumru OS, Liu J, Ji JYA, Cheng W, Wang YJ, Wang TT, et al. Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags. J Pharm Sci. 2012;101(10):3636\u201350.","journal-title":"J Pharm Sci"},{"issue":"9","key":"2368_CR19","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/j.2042-7158.2010.01153.x","volume":"62","author":"S Pescina","year":"2010","unstructured":"Pescina S, Ferrari G, Govoni P, Macaluso C, Padula C, Santi P, et al. In-vitro permeation of bevacizumab through human sclera: effect of iontophoresis application. J Pharm Pharmacol. 2010;62(9):1189\u201394.","journal-title":"J Pharm Pharmacol"},{"issue":"9","key":"2368_CR20","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1167\/iovs.15-16418","volume":"56","author":"N Celik","year":"2015","unstructured":"Celik N, Scheuerle A, Auffarth GU, Kopitz J, Dithmar S. Intraocular pharmacokinetics of Aflibercept and vascular endothelial growth factor-a. Invest Ophthalmol Vis Sci. 2015;56(9):5574\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2368_CR21","unstructured":"Avastin(R) [package insert]. Genentech, Inc., South San Francisco, CA; 2016. Available from: https:\/\/www.gene.com\/download\/pdf\/avastin_prescribing.pdf ."},{"key":"2368_CR22","unstructured":"Lucentis(R) [package insert]. Genentech, Inc., South San Francisco, CA; 2016. 2016 Available from: https:\/\/www.gene.com\/download\/pdf\/lucentis_prescribing.pdf ."},{"issue":"2","key":"2368_CR23","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1208\/s12249-012-9793-4","volume":"13","author":"TK Das","year":"2012","unstructured":"Das TK. Protein particulate detection issues in biotherapeutics development\u2014current status. AAPS PharmSciTech. 2012;13(2):732\u201346.","journal-title":"AAPS PharmSciTech"},{"issue":"3","key":"2368_CR24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/0168-3659(92)90169-R","volume":"18","author":"Friend DR. Invitro Skin Permeation Techniques","year":"1992","unstructured":"Friend DR. Invitro Skin Permeation Techniques. J Control Release. 1992;18(3):235\u201348.","journal-title":"J Control Release"},{"key":"2368_CR25","unstructured":"Chua HY, Agrawal RV, Wong TT, Preiser P, Venkatraman S. Optimal Buffer for Storage of Ranibizumab at Low Concentrations. In.ARVO. Seattle, WA; 2016."},{"key":"2368_CR26","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.survophthal.2010.09.001","volume":"56","author":"TT Kleinberg","year":"2011","unstructured":"Kleinberg TT, Tzekov RT, Stein L, Ravi N, Kaushal S. Vitreous substitutes: a comprehensive review. Surv Ophthalmol. 2011;56:300\u201323.","journal-title":"Surv Ophthalmol"},{"issue":"3\u20134","key":"2368_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10337-015-3017-5","volume":"79","author":"D Drljaca","year":"2016","unstructured":"Drljaca D, Asperger D, Ferencak M, Gavranic M, Babic S, Mikac I, et al. Comparison of four extraction methods for the determination of veterinary Pharmaceuticals in Sediment. Chromatographia. 2016;79(3\u20134):209\u201323.","journal-title":"Chromatographia"},{"issue":"2","key":"2368_CR28","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1001\/archopht.1990.01070040111042","volume":"108","author":"MW Johnson","year":"1990","unstructured":"Johnson MW, Olsen KR, Hernandez E, Irvine WD, Johnson RN. Retinal toxicity of recombinant tissue plasminogen-activator in the rabbit. Arch Ophthalmol. 1990;108(2):259\u201363.","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"2368_CR29","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1001\/archopht.118.5.659","volume":"118","author":"CJ Hrach","year":"2000","unstructured":"Hrach CJ, Johnson MW, Hassan AS, Lei B, Sieving PA, Elner VM. Retinal toxicity of commercial intravitreal tissue plasminogen activator solution in cat eyes. Arch Ophthalmol. 2000;118(5):659\u201363.","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"2368_CR30","first-page":"3466","volume":"34","author":"A Loewenstein","year":"1993","unstructured":"Loewenstein A, Zemel E, Lazar M, Perlman I. Drug-Induced Retinal Toxicity in albino rabbits - the effects of imipenem and Aztreonam. Invest Ophthalmol Vis Sci. 1993;34(12):3466\u201376.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"2368_CR31","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1136\/bjo.2003.027466","volume":"88","author":"SA Rowley","year":"2004","unstructured":"Rowley SA, Vijayasekaran S, Yu PK, McAllister IL, Yu DY. Retinal toxicity of intravitreal tenecteplase in the rabbit. Br J Ophthalmol. 2004;88(4):573\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"2368_CR32","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3341\/kjo.2012.26.5.378","volume":"26","author":"US Kim","year":"2012","unstructured":"Kim US, Oh HS, Kwon OW, Chung I, Lee SH, Lee JH. Effect of amiloride to retinal toxicity induced by tissue plasminogen activator. Korean J Ophthalmol. 2012;26(5):378\u201382.","journal-title":"Korean J Ophthalmol"},{"issue":"8","key":"2368_CR33","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1136\/bjo.2006.111260","volume":"91","author":"M Luke","year":"2007","unstructured":"Luke M, Januschowski K, Warga M, Beutel J, Leitritz M, Gelisken F, et al. The retinal tolerance to bevacizumab in co-application with a recombinant tissue plasminogen activator. Br J Ophthalmol. 2007;91(8):1077\u201382.","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"2368_CR34","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1016\/j.xphs.2017.08.011","volume":"106","author":"SM Singh","year":"2017","unstructured":"Singh SM, Bandi S, Jones DNM, Mallela KMG. Effect of Polysorbate 20 and Polysorbate 80 on the higher-order structure of a monoclonal antibody and its fab and fc fragments probed using 2D nuclear magnetic resonance spectroscopy. J Pharm Sci. 2017;106(12):3486\u201398.","journal-title":"J Pharm Sci"},{"key":"2368_CR35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0001-8686(03)00037-X","volume":"104","author":"P Attard","year":"2003","unstructured":"Attard P. Nanobubbles and the hydrophobic attraction. Adv Colloid Interf Sci. 2003;104:75\u201391.","journal-title":"Adv Colloid Interf Sci"},{"issue":"1\u20132","key":"2368_CR36","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cis.2010.01.006","volume":"154","author":"MA Hampton","year":"2010","unstructured":"Hampton MA, Nguyen AV. Nanobubbles and the nanobubble bridging capillary force. Adv Colloid Interf Sci. 2010;154(1\u20132):30\u201355.","journal-title":"Adv Colloid Interf Sci"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-018-2368-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-018-2368-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-018-2368-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T21:48:39Z","timestamp":1570830519000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-018-2368-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,28]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["2368"],"URL":"https:\/\/doi.org\/10.1007\/s11095-018-2368-7","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,28]]},"assertion":[{"value":"4 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors Steven A. Giannos and Edward R. Kraft own significant interest in the IP of the technology described. The authors Zhen-Yang Zhao, Kevin H. Merkley and Jiyang Cai have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}}],"article-number":"78"}}